These already led to the development of VX-770, the first and only FDA- and EMA-approved CFTR modulator, but only for the G551D-CFTR mutation19 and another 8 mutations20, which yet altogether only account for ~5% of all CF patients. Here, CFTR is linked to cystic fibrosis.